By weeks three and four, most people notice improvement
Together, we can navigate the path to a healthier, happier you
In the SURPASS clinical trials, which evaluated tirzepatide in over 10,000 patients with type 2 diabetes, participants experienced average reductions in total cholesterol of approximately 5-10%, LDL-C reductions of 6-13%, and triglyceride reductions of 15-25%, depending on the dose administered
The best candidates are individuals who arent diabetic, dont have a history of thyroid cancer, have not struggled with the health of their pancreas and have realistic expectations about their role in the success of their weight loss journey
Whatever the mechanism(s) of the triglyceride lowering in these MCS patients with T2DM and a genetic variant causing chylomicronemia, tirzepatide therapy resulted in a resolution of their chylomicronemia with a significant reduction in triglycerides